Breaking-News: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
By Alissa Gould, Boiron USA
On May 6, 2026, the U.S. Food and Drug Administration announced that it launched a one-day inspectional assessment pilot program. Essentially, instead of FDA relying on lengthy, comprehensive inspections every few years, the agency is testing short, targeted visits to determine if a facility appears compliant and low-risk.
Currently FDA annually conducts approximately 12,000 domestic inspections and 3,000 foreign inspections in more than 90 countries. The agency’s new “screening” model allows FDA to visit more sites and develop facility-specific risk scores. FDA will operate more efficiently by devoting staff time and resources for lengthier inspection at facilities identified for higher risk.
This pilot model presents both pros and cons for manufacturers. If finalized, the shorter one-day assessment will be less disruptive to production schedules, quality operations, and supply chain timing. For well-run OTC manufacturers that FDA has determined to be low-risk, the traditional multi-day inspections could become less frequent, and regulatory interactions may become more streamlined.
The new one-day program aims to allow FDA to reach more sites. For OTC manufacturers, this may increase the frequency  of the agency showing up. It may especially affect contract manufacturers or smaller OTC firms.
There may also be less advance warning and less time to organize responses, which means companies should always be “inspection-ready”. AAHP advises that homeopathic manufacturers will likely need: better documentation control, faster access to batch records and standard operating procedures (SOPs), and staff trained to respond immediately and concisely.
As FDA attempts to identify discrepancies between “registered and actual operations,” manufacturers should expect closer scrutiny of product listings, facility registrations, contract manufacturing relationships, quality unit responsibilities, electronic record systems, and batch traceability.
One-day inspectional assessments are not intended to replace standard FDA inspections. Instead, they serve as an additional tool to complement the agency’s existing approach. Investigators retain authority to expand the scope or duration of an assessment if warranted. The pilot does not represent a change in enforcement policy and does not apply to higher-risk or more complex facilities that require more comprehensive inspectional coverage.
Launch in April 2026, this pilot program will continue through fiscal year 2026 and be evaluated afterwards. Read more specifics about the program from FDA’s May 6 press release here: https://www.fda.gov/news-events/press-announcements/fda-launches-one-day-inspectional-assessments-strengthen-and-expand-oversight?utm_medium=email&utm_source=govdelivery